News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Novozymes Biopharma Expands Collaboration with Upperton Limited to Offer Customers New Albumin Conjugation Solution

12/8/2011 10:35:45 AM

NOTTINGHAM, UK - December 8, 2011 - Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has expanded its partnership with Nottingham-based research and development company, Upperton Limited, to offer customers a new albumin conjugation solution. By linking drugs to Novozymes' new Recombumin Flex recombinant human albumin (rAlbumin), using conjugation, their pharmacokinetic and pharmacodynamic properties can be dramatically enhanced. As a result, manufacturers can benefit from the ability to tailor and control the half-life of drugs to fit patients' medical needs.

"Novozymes is delighted to unveil Recombumin Flex along with our new conjugation solution in partnership with Upperton Limited," says Dave Mead, Business Development Director at Novozymes Biopharma. "Novozymes has enjoyed a successful relationship with Upperton over the past 10 years and its expertise and experience in the conjugation of proteins, combined with our experience of protein engineering and production, will help customers to design drugs with tailored serum half-life and fewer side-effects. This will result in improved dosing regimes for the patient and a reduction in overall costs for the healthcare provider."

By manipulating the interaction of albumin with its receptor, the neonatal Fc receptor (FcRn), Novozymes can produce modified albumins that bind with greater or lesser affinities, meaning a flexible half-life. Increasing the serum half-life of a drug may reduce the frequency of injections a patient receives or even reduce the amount of drug delivered, thereby significantly reducing toxic side-effects and increasing patient acceptance.

Upperton has demonstrated that proteins, peptides and small molecule APIs can be covalently attached to recombinant human albumin using a range of chemistries. Additionally, once drugs have been linked to the recombinant human albumin carrier, they exhibit dramatically improved pharmacokinetic and pharmacodynamic properties. Combining Novozymes' unique IP and know-how around the albumin molecules themselves with Upperton's rP-conjugateT albumin conjugation chemistry knowledge, enables the companies to work closely with customers to design and implement the best chemical linking approach for their molecule. As a result, Novozymes can provide partners with a unique service from initial product concept through to in vivo testing for developing novel drugs.

Richard Johnson, founder and CEO of Upperton Limited, comments "By combining Novozymes' and Upperton's unmatched expertise in our respective fields, we have developed a solution that solves industry challenges by enabling a tunable half-life that offers control and flexibility and has the potential to improve overall treatment efficacy."

To learn more about Novozymes' Recombumin Flex technology, please visit

To find out more about Upperton Limited, please visit

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace. Read more at


Novozymes Biopharma:

Sally Vernon, Customer Communications Manager

Tel. +44 115 955 3355



René Tronborg

Office: +45 4446 2274

Mobile: +45 3077 2274


Zhu Xiaoqing

Office: +86 106 298 7888+362

Mobile: +86 138 012 40590


Paige Donnelly

Office: +1 919 494 3209

Mobile: +1 919 218 4501


Saionara Ribeiro de Paula

Office: +55 41 3641 1112

Mobile: +55 41 9971 7225



Tobias Bjorklund

Office: +45 4446 8682

Mobile: +45 3077 8682


Thomas Steenbech Bomhoff

Mobile: +1 919 649 2565

Read at

comments powered by Disqus